SARS-CoV-2 vaccine + influenza vaccine + zoster vaccine recombinant

This entry refers to a vaccination regimen consisting of three distinct vaccines—SARS-CoV-2, inactivated influenza, and recombinant zoster (shingles)—evaluated in a prospective clinical study conducted by the Abramson Cancer Center at Penn Medicine. The study, titled "Vaccine Responses in Cancer" (NCT04775069), was designed to assess the immune responses and safety of these standard-of-care vaccinations in patients diagnosed with cancer. The regimen involves the administration of authorized SARS-CoV-2 vaccines (typically mRNA or viral vector platforms), annual inactivated influenza vaccines, and the recombinant zoster vaccine (Shingrix). The primary objective of the research is to understand how cancer and its treatments affect the immunogenicity of these essential vaccines in a vulnerable patient population.

Other names

SARS-CoV-2 vaccine-Abramson Cancer Center at Penn Medicine-influenza-COVID-19-herpes zosterSARS-CoV2 vaccine-Abramson Cancer Center at Penn Medicine-influenza-COVID-19-herpes zosterSARS-CoV 2 vaccine-Abramson Cancer Center at Penn Medicine-influenza-COVID-19-herpes zosterInfluenza vaccination + SARS-CoV-2 vaccine + Zoster Vaccine Recombinant